This is a pilot study to investigate the safety and feasibility of rhDNase1 and its impact on
neutrophil extracellular traps (NETs) in COVID-19 infected patients.
Phase:
Phase 1
Details
Lead Sponsor:
Exactis Innovation McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators:
Exactis Innovation Hamilton Health Sciences Corporation Hoffmann-La Roche Jewish General Hospital McGill University Health Centre/Research Institute of the McGill University Health Centre